Abivax's ARV action could herald functional HIV cure, says firm

By Dan Stanton

- Last updated on GMT

Related tags Clinical trial Protein Dna

A cure for HIV?
A cure for HIV?
A drug candidate which prevents the export of viral RNA in infected cells could lead the way in developing a functional cure for HIV, according to Abivax.

Abivax published details of the mechanism of action for its lead drug candidate ABX464 in the journal Retrovirology​ yesterday. CEO of the Paris, France-based company, Hartmut Ehrlich, said the small molecule has the potential to transform treatment for patients with the human immunodeficiency virus (HIV).

“If the in vivo data are confirmed in human clinical trials, ABX464 has the potential to change the way HIV patients are treated and could even become a cornerstone of a functional cure​,” he told in-Pharmatechnologist.com.

He explained that ABX464 prevents viral RNA being exported from the nucleus of a cell to the cytoplasm where protein synthesis takes place, mediated by a viral protein called Rev.

The molecule is the first under development to inhibit Rev and therefore it has the potential to “target both infected and non-infected cells,” ​Ehrlich said, “while traditional anti-retrovirals only prevent the infection of new cells.”

He revealed Abivax had received a lot of interest from Big Pharma about the candidate, adding the firm is planning to partner ABX464 for Phase III trials and commercialization, at least for North America and Europe, though he fell short at saying which firms specifically.

However, “the technology platform could work on other viral diseases as well, like dengue, chikungunya, hepatitis B and HSV, just to name a few.”​ He said, adding Abivax already had candidates against dengue and chikungunya in the preclinical stage.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us